Cartesian Q3 net loss $(24.2)M; cash $220.9M; Phase 3 Descartes-08 in MG expected 1H2025

Cartesian Therapeutics, Inc.

2024-Q3 EPS reported -$4.61 revenue$39,672,000

Cash and equivalents $220.9M as of Sep 30, 2024; runway expected into mid-2027.
Net loss $(24.2)M ($(1.13)/share) vs $(9.0)M ($(1.74)) in Q3 2023.
Research and development expenses $11.4M, down from $13.0M year-over-year.
Plan to commence Phase 3 trial of Descartes-08 in myasthenia gravis in 1H2025 after FDA meeting.
Completed $130M PIPE financing in July 2024; first patient dosed in Phase 2 SLE trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.